A5100842830- Schizophrenia research and treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Bipolar Disorder and Treatment
- Heart Failure Treatment and Management
- Parathyroid Disorders and Treatments
- Functional Brain Connectivity Studies
- Cardiovascular Function and Risk Factors
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Child and Adolescent Psychosocial and Emotional Development
- Tryptophan and brain disorders
- Electroconvulsive Therapy Studies
- Mental Health Research Topics
- Diabetes Treatment and Management
- Intensive Care Unit Cognitive Disorders
- Pharmacological Receptor Mechanisms and Effects
- Atherosclerosis and Cardiovascular Diseases
- Neurological and metabolic disorders
- Systemic Lupus Erythematosus Research
- Long-Term Effects of COVID-19
- HIV-related health complications and treatments
- Blood Pressure and Hypertension Studies
- Peptidase Inhibition and Analysis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
Université de Reims Champagne-Ardenne
2016-2025
Centre Hospitalier Universitaire de Reims
2016-2025
State Hospital
1987-2001
Los Angeles Clinical Trials
1993-1994
Metropolitan State University of Denver
1987-1990
University of California, Irvine
1989
Norwalk Hospital
1987
The focus of this study was the systematic evaluation clinical effects glycine as an adjunct to atypical antipsychotic clozapine in treatment schizophrenia.In a double-blind, placebo-controlled study, 19 patients with chronic, treatment-resistant schizophrenia who were maintained on optimal doses (400-1200 mg/day) administered either 30 g/day (N=9) or placebo (N=10) for 12 weeks. Clinical evaluations Brief Psychiatric Rating Scale, Scale Assessment Negative Symptoms, and Simpson-Angus...
We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared other cardiovascular and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). further wanted to determine incidence HF events and its consequences in these patient populations.International retrospective Postgraduate Course Heart Failure registry for COVID-19 CArdioVascular dyslipidaemia) was performed 28 centres from 15 countries (PCHF-COVICAV). The primary...
Precise data about ATTR-CM incidence rates at national level are scarce. Consequently, this study aimed to estimate the annual and survival of transthyretin amyloid cardiomyopathy (ATTR-CM) in France between 2011 2019 using real world data. We used French nationwide exhaustive (SNDS database) gathering in- out-patient claims. As there is no specific ICD-10 marker code for ATTR-CM, diagnosis required both amyloidosis (identified by E85. or a tafamidis meglumine delivery) cardiovascular...
In a controlled study, inpatient violence was measured during placebo, high-potency (haloperidol) and low-potency (chlorpromazine or clozapine) neuroleptics. Some patients had marked increase in violent behavior with the moderately high-dose haloperidol, but not The authors discuss reasons for increased including akathisia drug-induced behavioral toxicity.
Six treatment-resistant schizophrenic patients were given a ten-week single-blind trial of carbamazepine. Treatment resistance was determined on the basis documented failure to respond treatment with at least three neuroleptic drugs from two different chemical classes. The adjunctive use carbamazepine resulted in significant improvement negative symptoms schizophrenia. These are often poorly responsive conventional antipsychotic drugs. Therefore, controlled studies should be performed...
SRAMEK, JOHN PHARMD; HERRERA, PhD; COSTA, JEROME MD; HEH, CHRIS MD Author Information